Two prominent campaign groups are threatening legal action against the UK government over a controversial drug pricing deal with the United States, warning that a key provision could see British patients paying significantly more for essential medicines through the NHS.
The groups claim that proposed changes to how treatments are approved for NHS use represent an "unlawful power grab" that could undermine the health service's well-established ability to negotiate affordable drug prices. This system currently uses the NHS's substantial purchasing power - representing care for 66 million people - to secure better deals on medicines.
The agreement in question originated during Donald Trump's presidency and includes provisions for zero-tariff pharmaceuticals. Whilst this sounds beneficial on the surface, health campaigners have consistently raised concerns that such arrangements could weaken the NHS's negotiating position with powerful US pharmaceutical companies, potentially leading to higher costs for British taxpayers.
The specific concern centres on modifications to the regulatory framework governing new drug approvals. Campaign groups argue these changes could open the door to inflated drug prices, ultimately affecting both patient access to treatments and the long-term sustainability of our health service. They maintain that any alterations to these longstanding approval processes without proper parliamentary oversight and public consultation are both illegitimate and potentially unlawful.
This legal challenge reflects broader anxieties amongst health advocates about post-Brexit trade deals and their potential impact on the NHS. Many worry that the health service could become a bargaining chip in international negotiations, particularly with the US, which operates a fundamentally different healthcare system with markedly higher drug prices than the UK.
The government has repeatedly stated that "the NHS is not for sale" and insists that trade agreements will not compromise the service's founding principles or its ability to provide universal care. However, campaigners remain sceptical, citing limited transparency around key aspects of proposed deals. The threatened legal action could force ministers to publicly justify their position and provide clearer explanations of how any changes might affect NHS patients.
For UK patients, the stakes are considerable. Any significant increase in drug costs would place additional pressure on an already stretched NHS budget, potentially forcing difficult decisions about which treatments the service can afford to provide. This could affect access to innovative medicines and overall care quality - precisely the outcomes the NHS's current drug evaluation system is designed to prevent through its rigorous cost-effectiveness assessments.